JP2022529182A5 - - Google Patents

Info

Publication number
JP2022529182A5
JP2022529182A5 JP2021562045A JP2021562045A JP2022529182A5 JP 2022529182 A5 JP2022529182 A5 JP 2022529182A5 JP 2021562045 A JP2021562045 A JP 2021562045A JP 2021562045 A JP2021562045 A JP 2021562045A JP 2022529182 A5 JP2022529182 A5 JP 2022529182A5
Authority
JP
Japan
Prior art keywords
combination
pharmaceutically acceptable
levetiracetam
acceptable salt
therapeutic combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562045A
Other languages
English (en)
Japanese (ja)
Other versions
JP7730548B2 (ja
JP2022529182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028777 external-priority patent/WO2020214960A1/en
Publication of JP2022529182A publication Critical patent/JP2022529182A/ja
Publication of JP2022529182A5 publication Critical patent/JP2022529182A5/ja
Priority to JP2025133394A priority Critical patent/JP2025166119A/ja
Application granted granted Critical
Publication of JP7730548B2 publication Critical patent/JP7730548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562045A 2019-04-18 2020-04-17 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法 Active JP7730548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133394A JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835707P 2019-04-18 2019-04-18
US62/835,707 2019-04-18
US201962926130P 2019-10-25 2019-10-25
US62/926,130 2019-10-25
PCT/US2020/028777 WO2020214960A1 (en) 2019-04-18 2020-04-17 Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133394A Division JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Publications (3)

Publication Number Publication Date
JP2022529182A JP2022529182A (ja) 2022-06-17
JP2022529182A5 true JP2022529182A5 (cg-RX-API-DMAC10.html) 2023-04-25
JP7730548B2 JP7730548B2 (ja) 2025-08-28

Family

ID=72837945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562045A Active JP7730548B2 (ja) 2019-04-18 2020-04-17 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法
JP2025133394A Pending JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133394A Pending JP2025166119A (ja) 2019-04-18 2025-08-08 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法

Country Status (5)

Country Link
US (1) US20220193028A1 (cg-RX-API-DMAC10.html)
EP (1) EP3955905A4 (cg-RX-API-DMAC10.html)
JP (2) JP7730548B2 (cg-RX-API-DMAC10.html)
MA (1) MA55726A (cg-RX-API-DMAC10.html)
WO (1) WO2020214960A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240423953A1 (en) * 2021-01-26 2024-12-26 The Regents Of The University Of California Methods and compositions for targeting sv2 proteins for immune regulation
CN117771240A (zh) * 2023-12-05 2024-03-29 中国人民解放军海军军医大学 一种左乙拉西坦在制备减肥药物中的应用
WO2025212556A1 (en) * 2024-04-03 2025-10-09 Prevep, Inc. Formulations comprising seletracetam and methods of use
WO2025221463A1 (en) * 2024-04-19 2025-10-23 Prevep, Inc. Pharmaceutical compositions comprising atorvastatin, or a salt thereof, and a liquid carrier

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003175091A (ja) * 2001-10-03 2003-06-24 Nipro Corp 複室容器製剤
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
DE602004023510D1 (de) * 2003-07-15 2009-11-19 Ono Pharmaceutical Co Verzweigte carbonsäureverbindung und deren verwendung
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
EP1718308A4 (en) * 2004-02-11 2007-07-18 Painceptor Pharma Corp PROCESS FOR MODULATING NEUROTROPHINE-MEDIATED ACTIVITY
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
AU2009274571A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US20140239525A1 (en) * 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
EA034167B8 (ru) * 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
UA125747C2 (uk) * 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
JP2020513772A (ja) * 2016-12-28 2020-05-21 エクスペシコール エルエルシー 神経変性障害の非ヒト動物モデル
CN108379588B (zh) * 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物

Similar Documents

Publication Publication Date Title
RU2484815C2 (ru) Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
TWI618539B (zh) 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
Weinbroum et al. Dextromethorphan and dexmedetomidine: new agents for the control of perioperative pain
TWI405576B (zh) 疼痛疾病治療劑
US20080089861A1 (en) Combination therapy for treatment of demyelinating conditions
JP2018501299A5 (cg-RX-API-DMAC10.html)
US20050245460A1 (en) Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
CN1720025A (zh) 加巴喷丁片剂及其制备
JP2020524702A (ja) 免疫応答を調節するgabaの能力の強化
RS64481B1 (sr) Lečenje alchajmerove bolesti kod posebne populacije pacijenata
US10076506B2 (en) Baclofen formulations and methods for making same
US20230066347A1 (en) Ketamine treatment for amyotrophic lateral sclerosis
JP2021001221A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
US6372792B1 (en) Method for treating anxiety, anxiety disorders and insomnia
CZ111897A3 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
WO2023155837A1 (zh) 具有镇痛和/或止痒功能的药物组合物及其用途
RU2377983C2 (ru) Препарат l-триптофана, содержащий карбидопу/бенсеразид
Yaseen et al. Analgesic effects of magnesium sulphate in patients undergoing laparoscopic cholecystectomy
JP2025505578A5 (cg-RX-API-DMAC10.html)
JP2005531594A5 (ja) 慢性痛の治療用トリプルモノアミン再取り込み阻害剤
CN103012192B (zh) 一种新型乙酰谷酰胺化合物及其药物组合物
WO2022037006A1 (zh) 一种止痛止痒药物组合物及其应用方法
CN1137686C (zh) 椎管狭窄的治疗药
HK40069667A (en) Pharmaceutical composition with analgesic and/or antipruritic function and uses thereof
CN1929830A (zh) Nmda受体拮抗剂联合抗癫痫药物治疗癫痫症和其他中枢神经系统疾病的组合物和方法